Welcome to our dedicated page for Avient SEC filings (Ticker: AVNT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Avient’s color additives tint everything from recyclable food packaging to advanced medical devices, yet the business details sit deep inside dense SEC documents. If you’ve ever hunted for segment margins on specialty engineered materials or tried to confirm executive stock sales before resin price moves, you know why investors ask, "Avient SEC filings explained simply."
Stock Titan pulls every release the instant it hits EDGAR—whether it’s an Avient quarterly earnings report 10-Q filing that breaks down raw-material costs, an Avient annual report 10-K simplified that maps global demand for Color, Additives & Inks, or an Avient 8-K material events explained alert on unexpected supply-chain updates. Our AI-powered summaries translate accounting language into plain English, highlight segment revenue shifts, and flag sustainability commitments. Need to monitor Avient insider trading Form 4 transactions? Real-time dashboards track every Avient Form 4 insider transactions real-time entry so you can spot patterns before they surface in headlines.
Use the platform to:
- Compare quarter-over-quarter resin price impact with one-click Avient earnings report filing analysis
- Review Avient proxy statement executive compensation without paging through PDFs
- Set alerts for Avient executive stock transactions Form 4 and other filings
- Save hours by understanding Avient SEC documents with AI—from cash-flow tables to ESG footnotes
All filing types, one place, always current. Complex polymers may color the world, but your research doesn’t have to be complicated.
Insider purchase reported: Avient Corporation director Robert E. Abernathy acquired 1,192 shares of AVNT common stock on 09/30/2025 at no reported cash price, increasing his beneficial ownership to 38,560 shares. The Form 4 was signed on 10/02/2025 by Robert K. James as power of attorney. The filing indicates this is a single reporting person filing and shows direct ownership.
Avient Corp (AVNT) Form 4: The filing shows that David Nickolas Schneider, an officer (SVP, President SEM) of Avient, was granted 14,000 restricted stock units (RSUs) on 09/11/2025. Each RSU represents a contingent right to receive one share of Avient common stock. The RSUs are listed with an exercise/settlement date of 09/11/2028 and a reported price of $0, indicating these are time-vesting/award units rather than open-market purchases. The transaction was reported on the Form 4 dated 09/15/2025 and signed by Robert K. James as power of attorney for Schneider.
David Nickolas Schneider, listed as SVP and President SEM and a director/officer of Avient Corporation (AVNT), filed an Initial Form 3 reporting no securities beneficially owned as of the event date 09/08/2025. The filing was signed by Robert K. James as Power of Attorney on 09/12/2025. The form discloses the reporting persons role but records no direct or indirect ownership.
Franklin Mutual Advisers, LLC (FMA) filed Amendment No. 1 to Schedule 13G, detailing its passive ownership in Avient Corporation (AVNT) as of 30 June 2025.
- FMA beneficially owns 4,554,936 common shares, equal to 4.9 % of Avient’s outstanding stock.
- It reports sole voting power over 4,346,687 shares and sole dispositive power over the entire 4,554,936-share position; no shared power is disclosed.
- The filing is made under Rule 13d-1(b) as an institutional investment adviser; FMA certifies the shares were acquired in the ordinary course of business and not to influence control.
- Item 5 confirms ownership of 5 % or less, indicating the stake sits just below the regulatory threshold that would subject the investor to additional reporting and potential activism scrutiny.
This disclosure enhances visibility into Avient’s shareholder base but does not, on its face, signal any change in strategy or governance direction.
Avient (AVNT) posted solid Q2-25 results. Sales rose 2.0% YoY to $866.5 million, helped by 1.4 pp FX tailwind and strength in Defense and Healthcare. Gross margin expanded 180 bp to 32.1% as environmental charges eased, lifting operating income 33% to $96.1 million. Net income to common shareholders jumped 56% to $52.6 million and diluted EPS reached $0.57 versus $0.36 a year ago. Interest expense fell 7% on lower term-loan pricing.
Six-month figures are mixed. Sales inched up 0.9% to $1.69 billion but a $71.6 million non-cash impairment and $14.7 million hosting fees tied to the discontinued S/4HANA ERP project cut operating income 42% to $96.8 million and slashed EPS to $0.35 (-61%).
Balance sheet/liquidity: Cash declined to $474.5 million (-$70 million YTD) after $50 million voluntary term-loan prepayment and $49.4 million dividends. Total debt dipped to $2.05 billion; a new $500 million revolving credit facility maturing 2030 replaced the prior 2026 line, leaving $487 million availability and no borrowings outstanding. Net leverage remains above 3× EBITDA (exact ratio not disclosed).
Other highlights: Environmental accruals total $141.3 million, chiefly for the Calvert City barrier-wall project now under construction. The IRS continues to contest a $23.8 million 2019 capital-loss position; no reserve has been recorded. Segment mix improved: Color, Additives & Inks operating profit +5% YoY, while Specialty Engineered Materials -6% on higher maintenance spend. Capex was $39.5 million YTD, trending below prior year.
Avient Corporation (AVNT) Form 4 filing: Director Patricia Verduin disclosed the acquisition of 1,187 shares of Avient common stock on 06/30/2025. The transaction is coded “A” (acquired) with a stated price of $0, suggesting a grant or similar non-cash transaction. Following this filing, Verduin now directly owns 23,866 shares of AVNT. No sales or derivative security transactions were reported, and there were no indications of 10b5-1 plan usage. The Form was signed on 07/02/2025 by attorney-in-fact Robert K. James.